No Picture
News

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

FRISCO, Texas, May 31, 2022 /PRNewswire/ — Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on the ongoing first-in-human clinical trial of […]

[adinserter block="3"]
No Picture
Jobs

Manufacturing Science and Technology (MSAT) Principal Scientist – Cell and Gene Therapy (Global Technical Team) – Lonza – Houston, TX

The MSAT Principal Scientist supports optimization, standardization and harmonization of Cell and Gene Therapy (CGT) Operations.From Lonza – Tue, 31… Click here to view original post

[adinserter block="3"]
[adinserter block="3"]